{"id":754,"date":"2025-07-09T03:38:42","date_gmt":"2025-07-09T03:38:42","guid":{"rendered":"http:\/\/60.204.213.123\/?page_id=754"},"modified":"2025-07-09T03:39:33","modified_gmt":"2025-07-09T03:39:33","slug":"mart1-27-35-hla-a0201-5","status":"publish","type":"page","link":"https:\/\/www.guixiong.com.cn\/?page_id=754","title":{"rendered":"MART1 (27-35) HLA-A*02:01 \u6d41\u5f0f\u9a8c\u8bc1"},"content":{"rendered":"\n

\u9776\u70b9\u8bf4\u660e<\/h3>\n\n\n\n

MART1 (27-35) AAGIGILTV HLA-A*02:01<\/p>\n\n\n\n

<\/p>\n\n\n\n

HLA\u7c7b\u578b<\/h3>\n\n\n\n

HLA-A*02:01\uff0c \u4e2d\u56fd\u4eba\u5206\u5e03\u9891\u738712.036%<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

\u6297\u539f\u548cHLA\u7684\u4eb2\u548c\u529b<\/h3>\n\n\n\n

<\/p>\n\n\n\n

NetMHCpan 4.1<\/strong> <\/a> \u8ba1\u7b97AAGIGILTV\u4e0eHLA-A*02:01\u4eb2\u548c\u529b\u4e3a 3874.86 nM\u3002<\/p>\n\n\n\n

<\/p>\n\n\n\n

\u4ea7\u54c1\u7c7b\u578b\u548c\u5e94\u7528<\/h3>\n\n\n\n

<\/p>\n\n\n\n

\u4ea7\u54c1\u7c7b\u578b<\/td>\u89c4\u683c<\/td>\u4ef7\u683c<\/td><\/tr>
\u6d41\u5f0f\u68c0\u6d4b\u4e0e\u5206\u9009<\/td>MART1 (27-35) HLA-A*02:01 PE \/ APC \/ Alexa Fluor 488<\/td>7200\u5143\/50ug, 11800\u5143\/100ug<\/td><\/tr>
\u78c1\u73e0\u5206\u9009<\/td>MART1 (27-35) HLA-A*02:01 HLA-A*02:01\u78c1\u73e0<\/td>8200\u5143\/50ug, 12800\u5143\/100ug<\/td><\/tr>
\u751f\u7269\u7d20\u5316\u590d\u5408\u7269<\/td>MART1 (27-35) HLA-A*02:01 HLA-A*02:01-biotin<\/td>6800\u5143\/50ug, 11400\u5143\/100ug<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u5b9e\u6d4b\u7ed3\u679c<\/h3>\n\n\n\n

<\/p>\n\n\n\n

\u80bd\u523a\u6fc0PBMC\u540e\u68c0\u6d4b\u6297\u539f\u7279\u5f02\u6027CD8+T\u7ec6\u80de<\/h3>\n\n\n\n

AAGIGILTV\u591a\u80bd\u523a\u6fc0HLA-A*02:01\u9650\u5236\u6027PBMC\u540e\uff0c\u4f7f\u7528MART1 (27-35) HLA-A*02:01 PE \u56db\u805a\u4f53\u548c\u6297CD8-FITC\u6297\u4f53\u68c0\u6d4b\u3002\u4e0b\u56fe\u5de6\u56fe\u4e3a\u6297\u539f\u80bdAAGIGILTV\u523a\u6fc0\u7ec4\uff0c\u53f3\u56fe\u4e3a\u672a\u52a0\u6297\u539f\u80bd\u523a\u6fc0\u7ec4\u3002<\/p>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n

\u9776\u70b9\u7ed3\u5408\u7684TCR\u5e8f\u5217<\/h3>\n\n\n\n

\u8bf7\u67e5\u770bIEDB\u6570\u636e\u5e93<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

\u76f8\u5173\u6587\u7ae0<\/h3>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Reference - PMID<\/th>Reference - Journal<\/th>Reference - Date<\/th>Reference - Title<\/th>\n<\/tr>\n<\/thead>\n
7706734<\/td>J Immunol<\/td>1995<\/td>Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.<\/td>\n<\/tr>\n
7868898<\/td>J Immunol<\/td>1995<\/td>Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.<\/td>\n<\/tr>\n
8938271<\/td>Semin Cancer Biol<\/td>1995<\/td>Epitope selection and development of peptide based vaccines to treat cancer.<\/td>\n<\/tr>\n
9862732<\/td>J Immunol<\/td>1998<\/td>HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A\/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.<\/td>\n<\/tr>\n
10540322<\/td>Eur J Immunol<\/td>1999<\/td>H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.<\/td>\n<\/tr>\n
12972191<\/td>J Immunol Methods<\/td>2003<\/td>In situ detection of antigen-specific tumor-infiltrating lymphocytes using newly designed tetramers.<\/td>\n<\/tr>\n
15723046<\/td>Nat Biotechnol<\/td>2005<\/td>Directed evolution of human T-cell receptors with picomolar affinities by phage display.<\/td>\n<\/tr>\n
18424733<\/td>J Immunol<\/td>2008<\/td>Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.<\/td>\n<\/tr>\n
16197958<\/td>J Mol Biol<\/td>2005<\/td>Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants.<\/td>\n<\/tr>\n
17719062<\/td>J Mol Biol<\/td>2007<\/td>Structures of MART-126\/27-35 Peptide\/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.<\/td>\n<\/tr>\n
16455990<\/td>J Immunol<\/td>2006<\/td>Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.<\/td>\n<\/tr>\n
10958352<\/td>Tissue Antigens<\/td>2000<\/td>Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules.<\/td>\n<\/tr>\n
21093097<\/td>Immunobiology<\/td>2011<\/td>IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.<\/td>\n<\/tr>\n
17056587<\/td>J Immunol<\/td>2006<\/td>Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.<\/td>\n<\/tr>\n
18942640<\/td>Prostate<\/td>2009<\/td>The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.<\/td>\n<\/tr>\n
22952231<\/td>J Biol Chem<\/td>2012<\/td>T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.<\/td>\n<\/tr>\n
24550723<\/td>PLoS Comput Biol<\/td>2014<\/td>Computational design of the affinity and specificity of a therapeutic T cell receptor.<\/td>\n<\/tr>\n
21795600<\/td>J Immunol<\/td>2011<\/td>TCRs used in cancer gene therapy cross-react with MART-1\/Melan-A tumor antigens via distinct mechanisms.<\/td>\n<\/tr>\n
25198529<\/td>J Immunother<\/td>2014<\/td>TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation.<\/td>\n<\/tr>\n
11886495<\/td>J Invest Dermatol<\/td>2001<\/td>Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice.<\/td>\n<\/tr>\n
25505266<\/td>J Biol Chem<\/td>2015<\/td>Naturally processed non-canonical HLA-A*02:01 presented peptides.<\/td>\n<\/tr>\n
25589627<\/td>Clin Cancer Res<\/td>2015<\/td>Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.<\/td>\n<\/tr>\n
28489076<\/td>Nat Commun<\/td>2017<\/td>HLA-DP<sup>84Gly<\/sup> constitutively presents endogenous peptides generated by the class I antigen processing pathway.<\/td>\n<\/tr>\n
10916751<\/td>J Immunother<\/td>2000<\/td>Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.<\/td>\n<\/tr>\n
21937447<\/td>J Biol Chem<\/td>2011<\/td>Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design.<\/td>\n<\/tr>\n
23954306<\/td>J Mol Biol<\/td>2013<\/td>Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.<\/td>\n<\/tr>\n
30425106<\/td>Cancer Immunol Res<\/td>2019<\/td>High-Throughput Stability Screening of Neoantigen\/HLA Complexes Improves Immunogenicity Predictions.<\/td>\n<\/tr>\n
30700903<\/td>Nat Methods<\/td>2019<\/td>T cell antigen discovery via trogocytosis.<\/td>\n<\/tr>\n
30617019<\/td>Mol Ther<\/td>2019<\/td>Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.<\/td>\n<\/tr>\n
31091334<\/td>Eur J Immunol<\/td>2019<\/td>TCR-induced alteration of primary MHC peptide anchor residue.<\/td>\n<\/tr>\n
32184297<\/td>Cancer Immunol Res<\/td>2020<\/td>Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.<\/td>\n<\/tr>\n
32314731<\/td>Elife<\/td>2020<\/td>Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.<\/td>\n<\/tr>\n
11684128<\/td>J Immunol Methods<\/td>2001<\/td>Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells.<\/td>\n<\/tr>\n
32241816<\/td>Clin Cancer Res<\/td>2020<\/td>Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.<\/td>\n<\/tr>\n
34290406<\/td>Nature<\/td>2021<\/td>Phenotype, specificity and avidity of antitumour CD8<sup>+<\/sup> T cells in melanoma.<\/td>\n<\/tr>\n
36608422<\/td>Mol Immunol<\/td>2023<\/td>ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes.<\/td>\n<\/tr>\n
35874702<\/td>Front Immunol<\/td>2022<\/td>Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.<\/td>\n<\/tr>\n
35508657<\/td>Nature<\/td>2022<\/td>Landscape of helper and regulatory antitumour CD4<sup>+<\/sup> T cells in melanoma.<\/td>\n<\/tr>\n
37490916<\/td>Cell<\/td>2023<\/td>Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.<\/td>\n<\/tr>\n
26079729<\/td>J Immunol Methods<\/td>2015<\/td>Unpredicted phenotypes of two mutants of the TcR DMF5.<\/td>\n<\/tr>\n
23391568<\/td>Hum Immunol<\/td>2013<\/td>Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n

Views: 9<\/p>","protected":false},"excerpt":{"rendered":"

\u9776\u70b9\u8bf4\u660e MART1 (27-35) AAGIGILTV HLA-A*02:01 HLA\u7c7b\u578b HLA-A*02…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-754","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=754"}],"version-history":[{"count":7,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/754\/revisions"}],"predecessor-version":[{"id":1077,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/754\/revisions\/1077"}],"wp:attachment":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}